Evidence map›Paper›PMID 36501091›Full record

Trial reportNutrients2022

Plasma FGF21 Levels Are Not Associated with Weight Loss or Improvements in Metabolic Health Markers upon 12 Weeks of Energy Restriction: Secondary Analysis of an RCT.

Anouk Gijbels, Sophie Schutte, Diederik Esser, Charlotte C J R Michielsen, Els Siebelink, Monica Mars, Marco Mensink, Lydia A Afman

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Anouk GijbelsDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.ORCID 0000-0002-1128-5481
Sophie SchutteDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Diederik EsserDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Charlotte C J R MichielsenDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Els SiebelinkDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Monica MarsDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.ORCID 0000-0003-2010-1039
Marco MensinkDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.ORCID 0000-0002-9725-5709
Lydia A AfmanDivision of Human Nutrition and Health, Department of Agrotechnology and Food Sciences, Wageningen University & Research, Stippeneng 4, 6708 WE Wageningen, The Netherlands.
Wageningen University & Research · NL

Funding

Division of Human Nutrition and Health, Wageningen University, The Netherlands n/a
6 · The paper itself

Abstract

Recent studies suggest that circulating fibroblast growth factor 21 (FGF21) may be a marker of metabolic health status. We performed a secondary analysis of a 12-week randomized controlled trial to investigate the effects of two energy restriction (ER) diets on fasting and postprandial plasma FGF21 levels, as well as to explore correlations of plasma FGF21 with metabolic health markers, (macro)nutrient intake and sweet-taste preference. Abdominally obese subjects aged 40-70 years (

Indexed as

Fibroblast Growth FactorsWeight LossAdultAgedFastingHumansMiddle AgedObesityfibroblast growth factor 21Fibroblast Growth Factorscaloric restrictiondietary interventionenergy restrictionFGF21fibroblast growth factor 21liver fatmetabolic healthobesityoverweightweight loss

Identifiers

PMID36501091
PMCPMC9735516
OpenAlexW4310172048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.